HEMAB THERAPEUTICS HOLDINGS

COAGNASDAQ

🏆 #2183 by market capUS Equity

$287.43▲ $22.71 (+7.90%)

Simulated price

🔔

Track COAG

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 7.9%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1.55B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for COAG.

Trading Snapshot

Day Range: $286.08 – $290.16
52-Week Range: $23.00 – $55.42
Volume: $2.45B
Avg Volume: $2.12B
Shares Outstanding: 46.7M
Next Earnings: Nov 30, 2026

Fundamentals Snapshot

Annual Revenue: $112M
Last Q Revenue: $30M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own COAG

✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
✓Healthy economics — 40% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HEMAB THERAPEUTICS HOLDINGS

COAG

Financial Trends

Revenue (TTM)

$112M▲ +6.9% YoY

Gross Margin (TTM)

39.5%▲ +1.4% YoY

Operating Income (TTM)

$38M▲ +6.9% YoY

Free Cash Flow (TTM)

$15M▲ +6.9% YoY

StockOtter · stockotter.space

About HEMAB THERAPEUTICS HOLDINGS

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.

🦦